Brief: Adverum Biotechnologies Presents Positive End Of Study Results From Optic Trial In Wet AMD Including Two-Year Outcomes Following A Single Intravitreal Injection Of Ixo-Vec (Advm-022)

Adverum Biotechnologies

04/11/2022 16:11

Adverum Biotechnologies Inc  ADVM.O :
    * ADVERUM BIOTECHNOLOGIES PRESENTS POSITIVE END OF STUDY
RESULTS
FROM OPTIC TRIAL IN WET AMD INCLUDING TWO-YEAR OUTCOMES
FOLLOWING A SINGLE INTRAVITREAL INJECTION OF IXO-VEC (ADVM-022)
    * ADVERUM BIOTECHNOLOGIES INC - IXO-VEC WAS GENERALLY WELL
TOLERATED
    * ADVERUM BIOTECHNOLOGIES INC - ALL 2E11 PARTICIPANTS WERE
INFLAMMATION FREE AT END OF STUDY
    * ADVERUM BIOTECHNOLOGIES - 81% - 98% REDUCTION IN MEAN
ANNUALIZED
ANTI-VEGF INJECTIONS AFTER A SINGLE IVT INJECTION OF IXO-VEC
    * ADVERUM BIOTECHNOLOGIES-MEAN BEST-CORRECTED VISUAL ACUITY
(BCVA)
& CST MAINTAINED OR IMPROVED ACROSS BOTH 6E11 & 2E11 DOSES

Source text for Eikon:  ID:nGNXwYG2N 
Further company coverage:  ADVM.O